Comparing the current results to its competitors, Vistagen Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 504.92 % year on year. The sales growth was above Vistagen Therapeutics Inc 's competitors' average revenue growth of 4.34 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 504.92 % Vistagen Therapeutics Inc improved its market share, to approximately 0.01 %.
November 1, 2024
Vistagen Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, is actively engaged in the development of innovative therapies for psychiatric and neurological disorders. As part of its commitment to pioneering neuroscience applications, Vistagen utilizes nose-to-brain neurocircuitry to enhance drug delivery directly to the central nervous system, which is pivotal in treating mental health disorders. This article focuses on recent corporate developments, including upcoming financial reporting and intellectual property advancements, reflecting Vistagen s strategic efforts in the mental health sector. Corporate Update and Financial Reporting Vistagen has announced that it will h...
June 12, 2024
SOUTH SAN FRANCISCO, Calif. - Vistagen (Nasdaq: VTGN), the neuroscience-focused biopharmaceutical company, celebrated a year of extraordinary achievements as it recently announced its fiscal year 2024 financial results and provided an encouraging corporate update. Vistagen s unwavering dedication to developing groundbreaking therapies for psychiatric and neurological disorders, utilizing nose-to-brain neurocircuitry, has garnered significant attention within the industry.The fiscal year 2024 proved to be a significant turning point for Vistagen, as the company soared to new heights with impressive results that bolstered its reputation as a leader in the field. The company s tireless innovation, commitment to...
June 11, 2024
Vistagen, a neuroscience-focused biopharmaceutical company, has recently released its financial results for the fiscal year ended March 31, 2024. The company s groundbreaking approach to developing therapies for psychiatric and neurological disorders, based on nose-to-brain neurocircuitry, has yielded promising results and significant achievements. This article provides an overview of Vistagen s fiscal year 2024 performance and highlights key milestones in the company s pursuit of innovative treatment options.Fiscal Year 2024 Achievements:Vistagen s fiscal year 2024 has been marked by notable accomplishments, showcasing the company s dedication to transforming the landscape of psychiatric and neurological di...
Publicly Traded Peers of Vistagen Therapeutics Inc
Xenon Pharmaceuticals Inc Share Performance
-1.11%
Over The Past 5 Days
Xenon Pharmaceuticals Inc
Profile
Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.
Glaxosmithkline Plc's business model focuses on researching, developing, manufacturing, and marketing innovative healthcare products and medicines globally.
Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.
Gain Therapeutics inc's business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.
Sources:
Vistagen Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vistagen Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
